Get the Stockscreener App
8.03
2.82%
0.22
After Hours:
8.02
-0.010
-0.12%
Maplight Therapeutics Inc stock is traded at $8.03, with a volume of 600.79K.
It is up +2.82% in the last 24 hours and down -33.53% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$7.81
Open:
$7.84
24h Volume:
600.79K
Relative Volume:
1.51
Market Cap:
$446.27M
Revenue:
Net Income/Loss:
$-161.15M
P/E Ratio:
-2.1616
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-12.24%
1M Performance:
-33.53%
6M Performance:
-70.15%
1Y Performance:
+0.00%
1-Day Range:
$7.743
$8.43
1-Week Range:
$7.46
$9.415
52-Week Range:
$7.46
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
8.03 | 446.27M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-26 | Initiated | Guggenheim | Neutral |
| Aug-10-26 | Downgrade | UBS | Buy → Neutral |
| Jul-28-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Jun-25-26 | Initiated | Raymond James | Strong Buy |
| May-27-26 | Initiated | UBS | Buy |
| May-21-26 | Initiated | Craig Hallum | Buy |
| May-04-26 | Initiated | H.C. Wainwright | Buy |
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
Form 4 MapLight Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria
Form 4 MapLight Therapeutics Inc For: 26 September By Investing.com - Investing.com Australia
MapLight Therapeutics (MPLT) exec to sell shares under preset trading plan - stocktitan.net
MapLight Therapeutics, Inc. (MPLT) Stock Price Quote Today & Current Price Chart - Capital.com
MapLight Therapeutics to Participate in Upcoming Investor Conference - The Manila Times
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 5.3%Here's What Happened - MarketBeat
Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com Canada
Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com India
Maplight Therapeutics (NASDAQ:MPLT) Price Target Lowered to $43.00 at Needham & Company LLC - MarketBeat
Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Nan Fung Group Holdings Ltd Makes New $34.81 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 4.6%What's Next? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading 7.8% HigherShould You Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire
Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat
MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - stocktitan.net
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
MapLight Therapeutics (MPLT) grants CSO new options and RSUs - stocktitan.net
MapLight Therapeutics (MPLT) lifts GC stake with 31K options - stocktitan.net
MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet
Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan
MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Therapeutics announces $150M private placement - TipRanks
Morgan Stanley Maintains MapLight Therapeutics(MPLT.US) With Hold Rating, Maintains Target Price $21 - Moomoo
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - Moomoo
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
MapLight Therapeutics Announces $150 Million Private Placement Financing - marketscreener.com
MapLight bags USD 150m after muscarinic schizophrenia Phase II win - AllSci
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside - TradingView
Dividend HistoryMapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Reports Positive Phase 2 Schizophrenia Data, Plans Phase 3 Trial - Minichart
Needham raises MapLight Therapeutics price target to $45 - scanx.trade
Raymond James initiates coverage on MapLight Therapeutics with Strong Buy - scanx.trade
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028 - scanx.trade
MapLight Therapeutics Secures $150 Million Through Private Stock Placement - Kalkine Media
MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenses - Kalkine Media
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com India
MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary - TradingView
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal - Stock Titan
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com UK
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maplight Therapeutics Inc Stock (MPLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hanson Kristopher | Officer |
Sep 16 '26 |
Proposed Sale |
12.08 |
16,509 |
199,429 |
0 |
| Catalyst4, Inc. | 10% Owner |
Aug 14 '26 |
Buy |
11.38 |
4,400,000 |
50,072,000 |
25,306,689 |
| Lillie James Woodruff | Officer |
Aug 03 '26 |
Proposed Sale |
13.02 |
22,082 |
287,508 |
0 |
| Lillie James Woodruff | Chief Scientific Officer |
Aug 03 '26 |
Sale |
12.54 |
22,082 |
276,908 |
202,380 |
| Novo Holdings A/S | Former Affiliate |
Jul 30 '26 |
Proposed Sale |
15.02 |
1,600,000 |
24,032,000 |
0 |
| Catalyst4, Inc. | 10% Owner |
Jul 30 '26 |
Buy |
13.00 |
1,000,000 |
13,000,000 |
20,906,689 |
| Catalyst4, Inc. | 10% Owner |
Jul 29 '26 |
Buy |
12.63 |
3,000 |
37,890 |
19,906,689 |
| Catalyst4, Inc. | 10% Owner |
Jul 28 '26 |
Buy |
11.04 |
206,225 |
2,276,904 |
19,903,689 |
| Cox Troy | Director |
Jul 28 '26 |
Buy |
9.52 |
15,620 |
148,702 |
15,620 |
| Kroeger Christopher A. | Chief Executive Officer |
Jul 17 '26 |
Sale |
37.90 |
16,779 |
635,924 |
1,246,455 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):